Bipolar Disorder

The grounding supports a complex, multifactorial and heritable etiology rather than a single cause. Genome-wide studies identify many associated loci and implicate common genetic variation, including single-nucleotide polymorphisms and broader genomic influences. The literature also points to contributions from gene expression, transcriptomic, metabolomic, and gut microbiome-related factors.

Genetic findings link bipolar disorder risk to synaptic signaling pathways and to genes expressed in neurons of the prefrontal cortex and hippocampus. Cross-disorder analyses also highlight overlap with other psychiatric conditions, supporting shared biological pathways. The supplied literature further suggests involvement of gene expression regulation and broader systems such as the microbiome and metabolome, but does not define a single mechanism.

Heritable liability is a supported risk factor, with bipolar disorder described as highly genetic and multifactorial. The literature also indicates overlap with broader psychiatric genetic risk across disorders, but does not provide specific non-genetic risk factors in the supplied grounding. No additional risk factors are supported here.

Treatment guidance in the supplied grounding emphasizes pharmacological and psychological management with first-, second-, and third-line recommendations. Lithium is a co-studied drug, and the literature also notes signal enrichment in genes encoding targets of antipsychotics, calcium channel blockers, antiepileptics, and anesthetics. The grounding supports treatment at the modality or drug-class level only, without specifying regimens.